Casdin Partners GP, LLC 的 Form 4 申報
Standard Biotools Inc.（LAB），2024/8/6 申報
- 申報編號
- 0000919574-24-004280
- 申報時間
- 2024/8/6 21:58 ET
- 交易日
- 2024/8/2-8/5
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆非衍生性交易。公開市場買進合計 $194.9 萬。交易後 4 天申報。
這份申報後來被修正申報 0000919574-25-001776（2025/3/4）取代，網站的交易表改用修正後的版本。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Casdin Partners GP, LLCCIK 0001534260 | 董事、持股 10% 以上大股東 |
| Casdin Capital, LLCCIK 0001534261 | 董事、持股 10% 以上大股東 |
| Casdin EliCIK 0001534264 | 董事、持股 10% 以上大股東 |
| Casdin Partners Master Fund, L.P.CIK 0001534265 | 董事、持股 10% 以上大股東 |
| Casdin Private Growth Equity Fund, L.P.CIK 0001823061 | 董事 |
| Casdin Private Growth Equity Fund GP, LLCCIK 0001864554 | 董事 |
| Casdin Private Growth Equity Fund II, L.P.CIK 0001891102 | 董事 |
| Casdin Private Growth Equity Fund II GP, LLCCIK 0001919480 | 董事 |
| Casdin Amplify Fund, LPCIK 0002028254 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5462 to $1.6583. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5664 to $1.5997. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.